Skip to content

Study · Animal study (in vivo) · mouse · 2020

4 results

DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.

Wang W, Wen X, Duan W, Wang X, Chen Y, Dong J, Yang Z, Fang J, Zhou Z, Yao G, Fang Y, Huang Y

Journal of endocrinological investigation30 Nov 2019Cited by 2 (Europe PMC)

PMID31786794 (opens in a new tab)DOI10.1007/s40618-019-01153-z (opens in a new tab)PepBankPUB-31786794
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, dulaglutide produced glycemic control similar to DR10601 during an intraperitoneal glucose tolerance test.

    In plain wordsIn mice, dulaglutide controlled blood sugar similarly to DR10601 during a glucose tolerance test.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedIPGTT glycemic control
    Study

    mousen: not reported in source

    Comparator
    DR10601
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 nmol/kg · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    In an IPGTT, a single s.c. dose of DR10601 (30 nmol/kg) produced similar glycaemic control effects and a longer duration of action compared to dulaglutide (10 nmol/kg).
    1 context sentence
    Summary · context
    The antiobesity effects and improved glycaemic control of DR10601 in vivo were evaluated by administering DR10601 to high-fat DIO mice and ICR mice as a single dose or repeated s.c. doses once every 4 days for 24 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, dulaglutide had a shorter duration of glycemic action than DR10601.

    In plain wordsIn mice, dulaglutide controlled blood sugar for less time than DR10601.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDuration of glycemic action
    Study

    mousen: not reported in source

    Comparator
    DR10601
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 nmol/kg · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    In an IPGTT, a single s.c. dose of DR10601 (30 nmol/kg) produced similar glycaemic control effects and a longer duration of action compared to dulaglutide (10 nmol/kg).
    1 context sentence
    Summary · context
    The antiobesity effects and improved glycaemic control of DR10601 in vivo were evaluated by administering DR10601 to high-fat DIO mice and ICR mice as a single dose or repeated s.c. doses once every 4 days for 24 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat DIO mice, liraglutide had a nearly equivalent food-intake effect to DR10601.

    In plain wordsIn mice with diet-induced obesity, liraglutide affected food intake about as much as DR10601.

    Peptide
    Liraglutide
    Outcome
    No significant changeFood intake
    Study

    mousen: not reported in source

    high-fat DIO mice
    Comparator
    DR10601
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    40 nmol/kg daily · subcutaneous · 24 daysAs given in this study (mouse).

    Source sentences

    Summary
    Compared with that achieved with liraglutide (40 nmol/kg) s.c. administered daily, DR10601 administered s.c. once every 4 days at 90 nmol/kg exerted a nearly equivalent effect on food intake and significantly reduced the body weights of high-fat DIO mice at 24 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat DIO mice, body weight was higher with liraglutide than with DR10601 at 24 days.

    In plain wordsIn mice with diet-induced obesity, body weight was higher with liraglutide than with DR10601.

    Peptide
    Liraglutide
    Outcome
    IncreaseBody weight
    Study

    mousen: not reported in source

    high-fat DIO mice
    Comparator
    DR10601
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 nmol/kg daily · subcutaneous · 24 daysAs given in this study (mouse).

    Source sentences

    Summary
    Compared with that achieved with liraglutide (40 nmol/kg) s.c. administered daily, DR10601 administered s.c. once every 4 days at 90 nmol/kg exerted a nearly equivalent effect on food intake and significantly reduced the body weights of high-fat DIO mice at 24 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.